Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2003-09-25
2009-08-18
Haddad, Maher M (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S326000, C530S387100, C530S388100, C530S388250
Reexamination Certificate
active
07575872
ABSTRACT:
It is intended to provide an antibody showing immunoreactivity selectively to ADAMTS-13 and applications of this antibody in epitope analysis or diagnosis of an ADAMTS-13 autoantibody-positive patient. Alternatively, it is intended to provide a process for producing and use of a modified ADAMTS-13 molecule partially deleted aiming at the application in pharmaceutical products. An antibody specific for ADAMTS-13 which can be obtained from a warm-blooded animal immunized and sensitized with a polypeptide containing a part or the whole of ADAMTS-13 amino acid sequence; a process for producing an antibody comprising a step of immunizing and sensitizing a warm-blooded animal with a polypeptide containing a part or the whole of ADAMTS-13 amino acid sequence; use of the above-described antibody including a method of detecting and purifying ADAMTS-13; and a modified ADAMTS-13 molecule partially deleted are provided.
REFERENCES:
patent: 7037658 (2006-05-01), Ginsburg et al.
patent: 1152055 (2001-04-01), None
patent: WO 02/04441 (2002-01-01), None
patent: WO 02/88366 (2002-11-01), None
Chung and Fujikawa. Processing of von Willebrand factor by ADAMTS-13. Biochemistry. Sep. 17, 2002;41(37):11065-70.
Furlan et al. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. May 15, 1996;87(10):4223-34.
Zheng et al. The reference teachings anticipate the claimed invention.“Structure of von Willebrand factor-cleaving protease (ADAMTS13), a RT metalloprotease involved inThrombocytopenic purpura.”
Campbell A, General properties and applications of monoclonal antibodies, Elsevier Science Publishers, section 1.1, pp. 1-32, 1984.
Abaza MS, Atassi MZ. Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization: demonstration with region 94-100 (antigenic site 3) of myoglobin.. J Protein Chem. Oct. 1992;11(5):433-44.
Lederman S, et al. A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4. Mol Immunol. 28(11):1171-81, 1991.
Li CH, Yamashiro D, Tseng LF, Chang WC, Ferrara P. beta-Endorphin omission analogs: dissociation of immunoreactivity from other biological activities. Proc Natl Acad Sci U S A. 77(6):3211-3214, 1980.
Liu et al The AGDV residues on the gamma chain carboxyl terminus of platelet-bound fibrinogen are needed for platelet aggregation. Biochimica et Biophysica Acta 1343:316-326, 1997.
Y. Fujimura et al., “Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome”, Int. J. Hematol., (Jan. 2002), vol. 75, No. 1, pp. 25-34.
S. Cal et al., “Cloning expression analysis and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains”, Gene., Jan. 2002, vol. 283, No. 1-2, pp. 49-62.
DW Chung et al., “Processing of von Willebrand factor by ADAMTS-13”, Biochemistry, 2002, vol. 41, No. 37 pp. 11065-11070.
Osama Kanemitsu et al., “Kotai Kogaku Nyumon”, Chijinshokan Co., Ltd., Jan. 25, 1994, pp. 195-204, 145-166 and 115-124.
Barbara Plaimauer et al., “Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13)”, Blood, Nov. 15, 2002, vol. 100, No. 10, pp. 3626-3632.
Han-Mou Tsai et al., “Antibodies to von Willebrand Factor-Cleaving Preotease in Acute ThromboticThrombocytopenic purpura”, The New England Journal of Medicine, vol. 339, No. 22, Nov. 26, 1998, pp. 1585-1594.
Levy et al., “Mutations in a member of the ADAMTS gene family cause thromboticThrombocytopenic purpura”, Nature, vol. 413, Oct. 4, 2001, pp. 488-494.
Xinglong Zheng et al., “Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in ThromboticThrombocytopenic purpura”, The Journal of Biological Chemistry, vol. 276, No. 44, Nov. 2, 2001, pp. 41059-41063.
Helena E. Gerritsen et al., “Partial amino acid sequence of purified von Willebrand factor-cleaving protease”, Blood, vol. 98, No. 6, Sep. 15, 2001, pp. 1654-1661.
Koichi Kokame et al., “Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity”, PNAS, vol. 99, No. 18, pp. 11902-11907, Sep. 3, 2002.
Hamamoto Takayoshi
Maeda Hiroaki
Mimura Noriko
Nakagaki Tomohiro
Nozaki Chikateru
Bent Stephen A.
Foley & Lardner LLP
Haddad Maher M
Juridical Foundation The Chemo-Sero-Therapeutic Research Institu
LandOfFree
Antibody against von Willebrand factor cleaving enzyme and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody against von Willebrand factor cleaving enzyme and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody against von Willebrand factor cleaving enzyme and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4115209